Division of Diabetes, Endocrinology and Gastroenterology, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; Manchester Academic Health Sciences Centre, Manchester, UK; Wrightington, Wigan and Leigh NHS Trust, Wigan, UK.
Queen Alexandra Hospital, Portsmouth, UK.
Lancet Gastroenterol Hepatol. 2017 Nov;2(11):824-831. doi: 10.1016/S2468-1253(17)30250-9. Epub 2017 Sep 1.
The incidence of gastro-oesophageal reflux disease and Barrett's oesophagus is increasing. Barrett's oesophagus is the main precursor to oesophageal adenocarcinoma, which has a poor prognosis. In view of the vast potential burden of these diseases on patients and health-care resources, there is a real need to define and focus research efforts. This priority setting exercise aimed to produce a list of the top ten uncertainties in the field that reflect the priorities of patients and health-care providers. We adopted the robust and transparent methodologies previously outlined by the James Lind Alliance. This qualitative approach firstly involves an ideas gathering survey that, once distilled, generates a longlist of research uncertainties. These uncertainties are then prioritised via an interim ranking survey and a final workshop to achieve consensus agreement. The initial 629 uncertainties, generated from a survey of 170 individual respondents (47% professional, 53% non-professional) and one workshop, were narrowed down to the final top ten uncertainties of priority for future research. These priorities covered a range of issues, including a need for improved patient risk stratification, alternative diagnostic and surveillance tests, efficacy of a dedicated service for Barrett's oesophagus, cost-effectiveness and appropriateness of current surveillance, advances in development of non-drug treatments for gastro-oesophageal reflux disease, safety of long-term drug treatment, and questions regarding the durability and role of different endoscopic therapies for dysplastic Barrett's oesophagus. This is the first patient-centred assessment of priorities for researchers in this chronic disease setting. We hope that recognition and dissemination of these results will shape the future direction of research and translate into meaningful gains for patients.
胃食管反流病和巴雷特食管的发病率正在上升。巴雷特食管是食管腺癌的主要前体,其预后较差。鉴于这些疾病对患者和医疗资源的潜在巨大负担,确实有必要确定和集中研究工作。这项优先事项设定工作旨在列出该领域排名前十的不确定性,以反映患者和医疗保健提供者的优先事项。我们采用了詹姆斯林德联盟(James Lind Alliance)先前概述的稳健和透明的方法。这种定性方法首先涉及一个集思广益的调查,一旦经过提炼,就会产生一长串研究不确定性。然后通过中期排名调查和最终研讨会对这些不确定性进行优先级排序,以达成共识。最初的 629 个不确定性是从对 170 名个人受访者(47%为专业人士,53%为非专业人士)和一个研讨会的调查中产生的,经过筛选,最终确定了未来研究的十大优先不确定性。这些优先事项涵盖了一系列问题,包括需要改进患者风险分层、替代诊断和监测测试、巴雷特食管专用服务的疗效、当前监测的成本效益和适当性、开发非药物治疗胃食管反流病的进展、长期药物治疗的安全性,以及关于不同内镜治疗方法对异型性巴雷特食管的耐久性和作用的问题。这是首次对该慢性疾病患者中心评估研究人员的优先事项。我们希望这些结果的认识和传播将塑造未来的研究方向,并为患者带来有意义的收益。